$YCBD

cbdMD, Inc.

cbdMD is a consumer wellness company that develops, manufactures, markets and sells supplements and other products made with natural compounds, primarily hemp-derived cannabinoids. Its flagship cbdMD brand offers oils, gummies, capsules, soft-gels, topicals and hemp-derived Delta-9 THC products. Paw CBD sells tinctures, chews and topicals for dogs and cats, while ATRX offers functional ingredients such as mushrooms. Herbal Oasis sells hemp-derived THC-infused social seltzers that combine cannabinoids and nootropic mushrooms. cbdMD sells through its own e-commerce websites, online marketplaces, inside sales, wholesalers and retailers, including specialty health and pet channels and beverage distributors. Its products reach consumers through both online and brick-and-mortar sales, and it works with international distributors. The company uses in-house manufacturing and third-party contract manufacturers, and operates an 80,000-square-foot GMP-aligned warehousing and fulfillment facility. cbdMD is headquartered in Charlotte, North Carolina.

1
0
0

No SEC Form 4 filings for $YCBD in the last 30 days.

See all $YCBD insider activity →
Med

cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue

cbdMD, Inc. (YCBD) supports the Hemp Guardrails Act, bipartisan legislation introduced by Senators Sheehy and Klobuchar. The bill aims to establish federal standards for hemp-derived products, preventing a looming ban. cbdMD's CEO, Ronan Kennedy, highlights the bill's consumer protection and job preservation benefits. The company's recent acquisitions diversify its portfolio, reducing regulatory risks.

Patrick Ogle Takes 15.9% Stake in cbdMD, Gains Board Nomination Right

Patrick Ogle, via Akretive Holdings, acquired 2.23 million shares of cbdMD (15.9% stake) on October 30, 2026. The asset purchase agreement grants Akretive the right to nominate a director for cbdMD's committee, but not a guaranteed board seat. Akretive also holds a senior secured promissory note.

cbdMD, Inc. (YCBD): Completion of Acquisition or Disposition of Assets

cbdMD, Inc. (YCBD) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness Iconic supplement brands join cbdMD's portfolio, diversifying the company beyond hemp and positioning it "f

YCBD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning YCBD (cbdMD, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent YCBD coverage spans regulation, financial news and mergers & acquisitions.

What's driving YCBD

AlphAI scores every news story that mentions YCBD with an AI model for sentiment and relevance, and aggregates insider trades from cbdMD, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $YCBD

Score

cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue

cbdMD, Inc. (YCBD) supports the Hemp Guardrails Act, bipartisan legislation introduced by Senators Sheehy and Klobuchar. The bill aims to establish federal standards for hemp-derived products, preventing a looming ban. cbdMD's CEO, Ronan Kennedy, highlights the bill's consumer protection and job preservation benefits. The company's recent acquisitions diversify its portfolio, reducing regulatory risks.

$YCBDHighM&A· acquirer · completed

cbdMD, Inc. (YCBD): Completion of Acquisition or Disposition of Assets

cbdMD, Inc. (YCBD) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness Iconic supplement brands join cbdMD's portfolio, diversifying the company beyond hemp and positioning it "f

$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

$YCBDMedM&A· acquirer · definitive

cbdMD, Inc. (YCBD): Entry into a Material Definitive Agreement

cbdMD, Inc. (YCBD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women ’ s Beauty, Weight Loss and Longevity Wellness Agreement will add iconic supplement brands to cbdMD ’ s growing multi-brand consumer wellness platf

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

cbdMD, Inc. (NYSE American: YCBD) reported Q3 FY2026 results ended June 30, 2026. Revenue rose 20% year over year to $5.6 million, driven by 61% higher wholesale net sales and a full quarter contribution from Bluebird Botanicals. Oasis distribution expanded. Loss from operations was about $1.13 million. The company cited federal hemp legislation timing and expected monthly cost savings up to $150,000.

cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products

cbdMD, Inc. (NYSE American: YCBD) said a Senate continuing resolution released Aug. 2 would delay federal hemp restrictions on most hemp products from Nov. 12 to Dec. 11, preserving access to naturally derived full-spectrum CBD. The company said the language is not yet law and would need final House and Senate approval and presidential signature.

cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access

cbdMD, Inc. (NYSE American: YCBD) said it supports the bipartisan Lawful Hemp Protection Act by Reps. Andy Barr and Angie Craig, which would set a long-term federal regulatory framework for hemp-derived products. The company also backed an administration call to update the federal hemp definition before a Nov. 12, 2026 narrowing deadline under FY2026 appropriations.

cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation

cbdMD, Inc. (NYSE American: YCBD) said its Bluebird Botanicals brand partnered with Denver Audubon to support bird conservation in Colorado. Under the “Buy Bluebird, Save Bluebirds” campaign, Bluebird will contribute 1% of profits from Bluebird product sales over three months this summer. cbdMD said the move follows its investment in Bluebird after acquiring the brand.

Related tickers